Skip to content

EBIT at other companies

Nuvectis Pharma, Inc. logo
Nuvectis Pharma, Inc.NVCT
-$6.26M-12.4%
Allogene Therapeutics logo
Allogene TherapeuticsALLO
-$46.09M+29.3%
Regenxbio logo
RegenxbioRGNX
-$83.36M-787%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
Johnson & Johnson logo
Johnson & JohnsonJNJ
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Operating income-$10.8M-131%
Net income-$10.1M-122%
EPS (diluted)-$0.18-20.0%

Balance sheet

See full
Cash & equivalents$79.3M+398%
Total debt$1.0M-2.0%
Total equity$84.4M+779%
Total assets$95.8M+382%

Cash flow

See full
Operating cash flow-$9.8M-483%
CapEx$32.5K-52.0%
Free cash flow-$9.9M-462%

Valuation

See full
Market cap$691.97M+1,008%
Enterprise value$613.75M+1,190%

Returns & leverage

See full
Return on equity-74.4%-18.6pp
Debt / equity-0.1×
Current ratio8.8×+7.0×

Where this comes from

Calculated from Immix Biopharma, Inc.’s reported figures.

Plus components not separately reported this period.

The official record: Immix Biopharma, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immix Biopharma, Inc.'s ebit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Immix Biopharma, Inc.'s EBIT?
Immix Biopharma, Inc. (IMMX) reported EBIT of -$10.8M in Q1 2026.
How has Immix Biopharma, Inc.'s EBIT changed year-over-year?
Immix Biopharma, Inc.'s EBIT decreased by 130.7% year-over-year, from -$4.68M to -$10.8M.
What is the long-term trend for Immix Biopharma, Inc.'s EBIT?
Over 4 years (2021 to 2025), Immix Biopharma, Inc.'s EBIT has grown at a 117.0% compound annual growth rate (CAGR), from -$1.35M to -$29.96M.
What does EBIT mean?
Earnings before interest and taxes — the profit from the business before financing cost and tax. Uses reported operating income where a company reports it; otherwise pre-tax income plus interest expense. Lets companies be compared on earning power independent of capital structure.